Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kaneko, A.
Right arrow Articles by Suzuki, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaneko, A.
Right arrow Articles by Suzuki, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 33:601-607 (2003)
© 2003 Foundation for Promotion of Cancer Research

Review Article

Eye-Preservation Treatment of Retinoblastoma with Vitreous Seeding

Akihiro Kaneko and Shigenobu Suzuki+

Division of Ophthalmology, National Cancer Center Hospital, Tokyo, Japan

ABSTRACT

Retinoblastoma with vitreous seeding has been one of the most challenging conditions for eye-preservation therapy. Several modalities for treating vitreous seeding were reviewed in order to analyze the problems associated with them. External beam radiotherapy has been the most reliable method to treat vitreous seeding. However, recurrence after external beam radiotherapy needs other types of treatments to preserve the eyeballs. Due to the progress of investigations concerning retinoblastoma, chemotherapy has become the most promising method to cure not only recurrence but also primary tumors. Systemic chemotherapy can rarely cure vitreous seeding, but local chemotherapy using vitreous injections of melphalan can preserve about 50% of the eyeballs with vitreous seeding. Currently, animal experiments are being conducted to study the efficacy and safety of vitreous surgery combined with infusion of anticancer drugs for eradication of vitreous seeds and maintenance of visual function.

FOOTNOTES

+ For reprints and all correspondence: Akihiro Kaneko, Division of Ophthalmology, National Cancer Center Hospital, 5–1–1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. E-mail: akaneko{at}ncc.go.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 IOVSHome page
M. Tomi, M. Mori, M. Tachikawa, K. Katayama, T. Terasaki, and K.-i. Hosoya
L-Type Amino Acid Transporter 1-Mediated L-Leucine Transport at the Inner Blood-Retinal Barrier
Invest. Ophthalmol. Vis. Sci., July 1, 2005; 46(7): 2522 - 2530.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M. Munoz, M. Rosso, A. Perez, R. Covenas, R. Rosso, C. Zamarriego, J. A. Soult, and I. Montero
Antitumoral Action of the Neurokinin-1-Receptor Antagonist L-733,060 and Mitogenic Action of Substance P on Human Retinoblastoma Cell Lines
Invest. Ophthalmol. Vis. Sci., July 1, 2005; 46(7): 2567 - 2570.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.